PPCB NASDAQ
Camberwell, VIC 3124
AU
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kenyon Julian Norman | A-Award | 3,420,000 | — | 2021-08-17 |
| Nathanielsz James An | A-Award | 5,928,000 | — | 2021-08-17 |
| Nathanielsz James An | A-Award | 2,800,000 | — | 2021-08-17 |
| ZELINGER JOSEF | 0 | — | 2021-08-17 | |
| Campiciano Carlo M | 0 | — | 2019-06-24 |